Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Current Liabilities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Total Current Liabilities for 15 consecutive years, with $65.6 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 2.37% to $65.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65.6 million through Dec 2025, up 2.37% year-over-year, with the annual reading at $63.1 million for FY2025, 1.34% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $65.6 million at Aytu Biopharma, down from $66.0 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $109.4 million in Q2 2021, with the low at $61.3 million in Q3 2024.
  • Average Total Current Liabilities over 5 years is $74.4 million, with a median of $67.1 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities soared 355.67% in 2021, then plummeted 41.12% in 2022.
  • Over 5 years, Total Current Liabilities stood at $100.6 million in 2021, then plummeted by 33.23% to $67.1 million in 2022, then fell by 4.41% to $64.2 million in 2023, then decreased by 0.22% to $64.0 million in 2024, then grew by 2.37% to $65.6 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $65.6 million, $66.0 million, and $63.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.